OTC Pink: $WUHN) Pink Current
Market Cap 12,660,257 05/17/2019
Authorized Shares 100,000,000 05/17/2019
Outstanding Shares 42,271,310 05/17/2019
https://wuhn.org/
https://biodelta.net/
https://www.otcmarkets.com/stock/WUHN/security
https://www.nvsos.gov/sosentitysearch/CorpDet...&nt7=0
WHO WE ARE!
Wuhan General Group is a state of Nevada public corporation that trades on the OTC Market under the ticker symbol ‘’WUHN’’.
Wuhan General Group is an alternative medicinal and botanicals company focused on health application of Cannabidiol (CBD) and Psilocybin (magic mushroom) based medicine to the human care industry for cancer, cardiovascular, mental disorders, chronic pain, Chrohn diseases, arthritis, and others in South Africa, Canada, United States, and Europe.
Wuhan General Group operates through its wholly-owned subsidiary MJ MedTech, a nutraceutical biotechnology company that research, develops and commercializes a range of CBD-based products under the Dr. Anna brand.
In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine and clinical research.
We are committed to supplying medical grade CBD products, superior patient care while increasing shareholders ROI. We’re on track to achieve a positive cash flow in the second quarter of 2019. According to a new estimate from cannabis industry analysts the Brightfield Group, the CBD market alone could hit $22 billion by 2022.
LATEST NEWS IN DENVER
DENVER — The Mile High City has become the first U.S. city to decriminalize psilocybin mushrooms, commonly referred to as "magic mushrooms."
Initiative 301 narrowly squeaked by, passing with only 50.56% of the vote, according to the final unofficial results. The measure appeared to be losing in early returns, with the "no" votes holding a substantial lead.
The initiative would effectively decriminalize use or possession of psilocybin by people 21 and older, making it the lowest enforcement priority for police and prosecutors. The measure does not legalize psilocybin or permit its sale by cannabis businesses.
The ordinance would also prevent city funds from being used to pursue criminal penalties on possession or use and create a panel to study the effects of the change.
The group responsible for the measure, Decriminalize Denver, followed the same tack taken by marijuana activists to decriminalize pot possession in 2005 in the city. That move was followed by statewide legalization in 2012.
Psilocybin mushrooms are federally classified as an illegal drug by the U.S. Drug Enforcement Agency.
https://www.thedenverchannel.com/news/local-n...om-measure
https://www.youtube.com/watch?v=O6jQwpnyFP0
https://www.youtube.com/watch?v=ftNI7v0gMs4
~ Researchers from Johns Hopkins University have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic drug to one day treat depression and anxiety and help people stop smoking.
~ Its potential indications include depression, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, cluster headaches, and cancer-related or other end-of-life psychological distress.
Latest WUHN NEWS !!
Wuhan Enters Mushroom Psychedelic Medicine Market April 05, 2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=223990
Wuhan Expands Capacity to Produce Medicinal Marijuana and Mushrooms May 17, 2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=228824
Wuhan Updates on Hemp and CBD-Based Products Line 03/29/2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=223014
Cosmetic
Day Cream
Night Cream
Facial Cleanser
Facial Exfoliator
Anti-Aging
Shampoo & Conditioner
SPF 50+ Sunblock
Food
CBD Olive Oil
CBD Salad Dressing
Infused Coffee
Infused Tea
Infused Honey
CBD Chocolate
In Phase 2 and 3, the range of products will fall under the Topicals and CAMS (Complementary and Alternative Medicines) segment, respectively. The Company is expected to launch its range of Phase 2 and 3 products to the market in Q4 2019 onward.
Topicals
CBD Balms for pain and inflammation
CBD Ointments for joint care
CBD Creams for mind and mood
Soft gels
CAMS
Capsules
Suppositories
CBD Extracts
Antioxidants
Immune Booster
Multivitamins
The Company forecasts revenues for Q2, Q3 and Q4 2019 of the amount of $585,000, $2,047,500 and $5,265,000, respectively.
Company used to be on the NASDAQ Company delisted from NASDAQ on 06/15/12 for not being over $1.00 PPS
Market Cap 12,660,257 05/17/2019
Authorized Shares 100,000,000 05/17/2019
Outstanding Shares 42,271,310 05/17/2019
https://wuhn.org/
https://biodelta.net/
https://www.otcmarkets.com/stock/WUHN/security
https://www.nvsos.gov/sosentitysearch/CorpDet...&nt7=0
WHO WE ARE!
Wuhan General Group is a state of Nevada public corporation that trades on the OTC Market under the ticker symbol ‘’WUHN’’.
Wuhan General Group is an alternative medicinal and botanicals company focused on health application of Cannabidiol (CBD) and Psilocybin (magic mushroom) based medicine to the human care industry for cancer, cardiovascular, mental disorders, chronic pain, Chrohn diseases, arthritis, and others in South Africa, Canada, United States, and Europe.
Wuhan General Group operates through its wholly-owned subsidiary MJ MedTech, a nutraceutical biotechnology company that research, develops and commercializes a range of CBD-based products under the Dr. Anna brand.
In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine and clinical research.
We are committed to supplying medical grade CBD products, superior patient care while increasing shareholders ROI. We’re on track to achieve a positive cash flow in the second quarter of 2019. According to a new estimate from cannabis industry analysts the Brightfield Group, the CBD market alone could hit $22 billion by 2022.
LATEST NEWS IN DENVER
DENVER — The Mile High City has become the first U.S. city to decriminalize psilocybin mushrooms, commonly referred to as "magic mushrooms."
Initiative 301 narrowly squeaked by, passing with only 50.56% of the vote, according to the final unofficial results. The measure appeared to be losing in early returns, with the "no" votes holding a substantial lead.
The initiative would effectively decriminalize use or possession of psilocybin by people 21 and older, making it the lowest enforcement priority for police and prosecutors. The measure does not legalize psilocybin or permit its sale by cannabis businesses.
The ordinance would also prevent city funds from being used to pursue criminal penalties on possession or use and create a panel to study the effects of the change.
The group responsible for the measure, Decriminalize Denver, followed the same tack taken by marijuana activists to decriminalize pot possession in 2005 in the city. That move was followed by statewide legalization in 2012.
Psilocybin mushrooms are federally classified as an illegal drug by the U.S. Drug Enforcement Agency.
https://www.thedenverchannel.com/news/local-n...om-measure
https://www.youtube.com/watch?v=O6jQwpnyFP0
https://www.youtube.com/watch?v=ftNI7v0gMs4
~ Researchers from Johns Hopkins University have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic drug to one day treat depression and anxiety and help people stop smoking.
~ Its potential indications include depression, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, cluster headaches, and cancer-related or other end-of-life psychological distress.
Latest WUHN NEWS !!
Wuhan Enters Mushroom Psychedelic Medicine Market April 05, 2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=223990
Wuhan Expands Capacity to Produce Medicinal Marijuana and Mushrooms May 17, 2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=228824
Wuhan Updates on Hemp and CBD-Based Products Line 03/29/2019
https://www.otcmarkets.com/stock/WUHN/news/Wu...?id=223014
Cosmetic
Day Cream
Night Cream
Facial Cleanser
Facial Exfoliator
Anti-Aging
Shampoo & Conditioner
SPF 50+ Sunblock
Food
CBD Olive Oil
CBD Salad Dressing
Infused Coffee
Infused Tea
Infused Honey
CBD Chocolate
In Phase 2 and 3, the range of products will fall under the Topicals and CAMS (Complementary and Alternative Medicines) segment, respectively. The Company is expected to launch its range of Phase 2 and 3 products to the market in Q4 2019 onward.
Topicals
CBD Balms for pain and inflammation
CBD Ointments for joint care
CBD Creams for mind and mood
Soft gels
CAMS
Capsules
Suppositories
CBD Extracts
Antioxidants
Immune Booster
Multivitamins
The Company forecasts revenues for Q2, Q3 and Q4 2019 of the amount of $585,000, $2,047,500 and $5,265,000, respectively.
Company used to be on the NASDAQ Company delisted from NASDAQ on 06/15/12 for not being over $1.00 PPS
